From cargo surveys to £10.9bn takeover: How Intertek became EQT’s prized target

Intertek Group plc (LSE: ITRK) is preparing to return to private ownership nearly 30 years after a private equity buyout created the modern Intertek business and 24 years after the company listed in London. EQT’s recommended £60-per-share cash offer, combined with a 107.7 pence final dividend for eligible shareholders, values Intertek at approximately £10.9 billion including debt and the retained dividend. Yet the transaction is more than another large public-to-private deal involving a FTSE 100 company. It closes a corporate circle around a business assembled from marine surveying, chemical testing and electrical safety operations, while turning a public-market valuation debate into a private equity experiment in consolidation, technology and portfolio design. The deeper story is why quality assurance, long regarded as an unglamorous support service, has become valuable enough to justify one of Britain’s largest take-private transactions.

How did Intertek grow from Victorian cargo inspection into a global assurance network?

Intertek’s roots reach back to the late nineteenth century, when independent testing was emerging as a practical response to expanding international trade and industrialisation. Caleb Brett established a marine surveying business that inspected and certified cargoes before shipment, while Milton Hersey created an independent chemical testing laboratory in Montreal. Thomas Edison’s Lamp Testing Bureau added another strand to the company’s eventual history by developing methods for evaluating electrical products and performance.

These businesses were created in different countries and served different industries, but they addressed the same commercial problem. Buyers, sellers, governments and insurers needed trusted evidence that a product or cargo met an agreed standard. The underlying product could be grain, chemicals, steel or electric lighting, but the economic value came from reducing uncertainty between parties that could not independently verify every claim.

The businesses that eventually formed Intertek were consolidated through Inchcape during the twentieth century. In 1996, Charterhouse Development Capital acquired Inchcape Testing Services for approximately £380 million and renamed it Intertek. That transaction was important because it established the integrated global platform that would later become a London-listed company.

Intertek joined the London Stock Exchange in May 2002 at £4 per share with a market capitalisation of approximately £614 million. At the time, Intertek employed around 10,500 people and operated roughly 750 laboratories and offices. The company has since expanded to approximately 45,000 employees and more than 1,000 laboratories and offices across over 100 countries.

The comparison between the 2002 listing value and the current takeover valuation demonstrates how strongly the economics of assurance have compounded. Intertek did not become valuable by inventing one blockbuster product. It built value by becoming embedded in thousands of recurring decisions involving product launches, international shipments, infrastructure projects, energy assets, food safety and corporate compliance.

Why has testing and certification become an unusually attractive private equity business?

Testing, inspection, assurance and certification services occupy an unusual position in a customer’s cost structure. The cost of testing a product or inspecting an asset is generally small relative to the total development, manufacturing or construction budget. The cost of failing a safety requirement, delaying market entry or operating a defective asset can be considerably larger.

That asymmetry gives testing providers pricing resilience. Customers may negotiate over fees, but they cannot casually eliminate services required by regulators, retailers, insurers or internal risk controls. Testing is therefore less discretionary than many other outsourced services, particularly where a certificate or independent assessment is necessary before a product can be sold.

The business also benefits from rising complexity. Modern products combine software, electronics, batteries, connected systems, chemicals and international components. A manufacturer may need to satisfy several regulatory regimes before launching the same product across Europe, North America, India and Asia. That increases demand for providers capable of coordinating testing and certification across multiple jurisdictions.

Intertek’s scale provides an additional advantage. Customers can use a global provider instead of managing separate local laboratories in every market. Intertek can also spread investment in equipment, accreditation, data systems and specialised expertise across a large client base.

For private equity investors, these characteristics create an appealing combination of recurring demand, defensible customer relationships, cash generation and acquisition opportunities. A laboratory may not have the glamour of a software platform, but dependable cash flows have a charm of their own, particularly when debt financing is involved.

What did Intertek’s London listing reveal about the compounding power of compliance demand?

Intertek’s growth as a listed company was not perfectly linear. Individual divisions were affected by commodity cycles, industrial investment, foreign exchange movements, customer research budgets and changing product demand. However, the broader requirement for independent assurance continued to expand as supply chains became more global and regulatory expectations increased.

Intertek generated revenue of £3.43 billion in 2025 and adjusted operating profit of approximately £620 million. Its adjusted operating margin reached 18.1%, while adjusted operating cash flow totalled £762 million. Those figures illustrate why the company attracted a buyer willing to pay a substantial premium.

The most important number may not be annual revenue or profit, but the cumulative operating cash flow of £2.3 billion generated during the three years following the launch of Intertek’s AAA growth strategy in 2023. The company used that cash to fund organic investment, bolt-on acquisitions, dividends and share repurchases.

This is the compounding model that EQT is buying. Revenue growth creates operating leverage, margin improvement strengthens cash generation and cash can then be reinvested into additional laboratories, digital products or acquisitions. The cycle is not explosive, but it can become powerful when repeated across a global network.

Intertek also has a diversified customer base. No individual customer accounted for more than 10% of group revenue in 2025. That reduces dependence on any single contract and makes the business easier to finance than a services company reliant on a small number of large clients.

The public market nevertheless struggled to assign a consistently high valuation to the company. Investors could see the cash flows, but they also saw a portfolio containing consumer testing, corporate assurance, pharmaceuticals, food, minerals, oil and gas, infrastructure and transportation. Diversity reduced risk, yet it also complicated the valuation narrative.

Why did Intertek consider breaking itself into two specialist global assurance companies?

Intertek’s own strategic review began before the EQT transaction was agreed. The company was evaluating whether Intertek Testing and Assurance should remain under the same ownership as Intertek Energy and Infrastructure.

Intertek Testing and Assurance included Consumer Products, Corporate Assurance and Health and Safety. These businesses generated approximately £1.86 billion of revenue in 2025 and had exposure to consumer brands, supply-chain compliance, food testing, pharmaceutical services, cybersecurity, sustainability and corporate risk.

Intertek Energy and Infrastructure generated approximately £1.58 billion of revenue. Its operations covered industry services, minerals, building and construction, commodity inspection and transportation technologies. Its performance was more closely linked to infrastructure investment, mining activity, energy markets and industrial capital expenditure.

The proposed separation reflected an increasingly common corporate strategy argument. A diversified group can benefit from scale, shared systems and customer relationships, but distinct businesses may receive higher valuations when investors can assess their growth, margins and capital needs independently.

Intertek believed the two operations had limited shared costs and sufficiently developed management structures to operate separately. A separation could have created a higher-margin testing and assurance company alongside an energy and infrastructure platform positioned for consolidation.

The strategic review also exposed the valuation opportunity that EQT ultimately pursued. Once Intertek publicly acknowledged that its portfolio might be worth more in separate parts, the debate shifted from whether value was hidden to who should capture it. Public shareholders could wait for a sale or demerger, or accept immediate cash from a buyer prepared to undertake the restructuring itself.

What does EQT believe it can unlock that public investors had not fully rewarded?

EQT’s approach progressed through proposals of £51.50, £54, £58 and ultimately £60 per share. Intertek rejected the first three approaches before recommending the final proposal, which allowed eligible shareholders to retain the 107.7 pence final dividend.

The sequence indicates that EQT was not simply buying a stable income stream. The persistence suggests a conviction that Intertek offers several additional value-creation levers. These include portfolio restructuring, technology investment, bolt-on acquisitions, operational productivity and a potential exit through a sale or renewed public listing.

Private ownership would allow EQT to evaluate individual divisions without the immediate pressure of quarterly market expectations. Businesses could be sold, combined or given additional capital based on their strategic position rather than their contribution to a simplified public-company narrative.

Intertek could also accelerate acquisitions. The global testing market remains fragmented, with numerous specialist laboratories serving particular industries, technologies or geographies. Intertek can acquire smaller operators and connect them to its international customer network, procurement capabilities and data systems.

The risk is that readily available capital can encourage acquisition volume rather than acquisition quality. Laboratories depend on specialist employees, technical credibility and local accreditation. A business can be acquired quickly, but scientific expertise and customer trust cannot be integrated by spreadsheet alone.

EQT’s challenge will be to increase the economic output of Intertek’s network without weakening the independence and reliability that make customers willing to pay for its services.

How could digital workflows and artificial intelligence alter Intertek’s laboratory economics?

Intertek’s operations are physical, scientific and labour-intensive, but the surrounding workflow is increasingly digital. Test requests, product specifications, sample tracking, customer communication, certification records and regulatory reporting can all be managed through connected platforms.

Automation can reduce administrative work and improve the utilisation of laboratories. A global system could direct work to facilities with available capacity, identify recurring customer requirements and shorten the time between receiving a sample and issuing a result.

Artificial intelligence could support document review, anomaly detection, image analysis and the interpretation of large testing datasets. It may also create a new category of assurance services as companies seek independent verification of artificial intelligence models, connected devices and automated decision systems.

The opportunity is not to remove scientists and inspectors from the process. It is to allow technical employees to spend more time on analysis, customer problems and complex judgments while software handles repetitive data processing.

Digital investment could therefore improve both revenue and margins. Faster turnaround times may attract additional customers, while lower administrative costs can increase laboratory profitability. Common systems may also make acquired businesses easier to integrate.

However, technology creates new risks. Intertek handles sensitive product information, technical data and commercial plans. Cybersecurity, model accuracy and data governance will become more important as digital systems assume a larger role in testing and certification.

Why will acquisition discipline matter more than simple cost cutting under private ownership?

Large private equity transactions are often associated with aggressive cost reduction, but Intertek’s long-term value depends primarily on growth and trust. Excessive cost cutting could reduce scientific capacity, slow turnaround times or damage customer relationships.

There may be opportunities to simplify central functions once Intertek is no longer listed. Public reporting, investor relations and duplicated administrative processes can be reviewed. Yet the larger opportunity lies in directing capital toward attractive testing categories and geographies.

Intertek invested more than £300 million in organic and inorganic growth during 2025. The company completed four acquisitions during the year and has used bolt-on deals to expand in areas including environmental analysis, workforce training, metallurgical testing, food safety and medical-device services.

Under EQT, acquisition spending could increase. The buyer consortium includes Luxinva, a subsidiary of Abu Dhabi Investment Authority, and Mubadala Investment Company. Their participation provides additional equity capacity and aligns Intertek with long-duration institutional capital.

Financing remains a constraint. The takeover will use a combination of equity commitments and interim debt facilities. Intertek already carried net financial debt of almost £1 billion at the end of 2025 after investing in growth and returning capital to shareholders.

If the post-transaction structure carries substantial additional leverage, management will have to balance interest payments, capital expenditure and acquisitions. Strong cash generation makes that balance possible, but a slowdown in industrial activity or an acquisition integration problem could reduce flexibility.

The best outcome would use debt as a disciplined capital tool while preserving investment in laboratories, technology and employees. The weaker outcome would prioritise rapid deleveraging at the expense of the growth thesis used to justify the purchase price.

How might the Intertek takeover change competition across global testing and certification?

Intertek competes with international groups including SGS, Bureau Veritas and Eurofins Scientific, as well as hundreds of specialist regional companies. The EQT transaction could alter competition by giving Intertek greater freedom to pursue acquisitions and long-term technology investments.

Peers may respond by accelerating their own dealmaking. Attractive laboratories with exposure to batteries, artificial intelligence, cybersecurity, medical devices, minerals, renewable energy and food safety could become more valuable as larger groups compete for capabilities.

The transaction may also encourage investors to reassess the valuation of other testing and certification companies. Intertek’s takeover premium suggests that public-market prices may not fully reflect the strategic value of global laboratory networks, accreditations and recurring compliance relationships.

Customers could benefit from broader service capabilities and more integrated international platforms. However, continued consolidation may reduce the number of independent providers in specialised markets. Regulators will therefore examine whether acquisitions weaken customer choice or create conflicts in certification and inspection.

The competitive battle will increasingly extend beyond physical laboratory capacity. Companies will compete on turnaround time, digital access, regulatory intelligence, data integration and the ability to support customers throughout a product’s lifecycle.

Intertek’s future under EQT could therefore influence how the entire sector allocates capital. If the strategy succeeds, rivals may face pressure to modernise faster and pursue larger acquisitions. If it disappoints, the industry may rediscover that steady scientific businesses do not always respond well to financial acceleration.

Why does another FTSE 100 take-private deepen concern about London’s valuation problem?

Intertek’s proposed departure would remove another internationally diversified company from the London Stock Exchange. The transaction follows a wider pattern in which private equity firms and overseas buyers have targeted UK-listed companies trading at valuations below comparable international assets.

The immediate outcome is attractive for shareholders receiving a substantial cash premium. The longer-term consequence for the market is less positive. London loses a profitable global company with recurring revenue, strong cash generation and exposure to structural growth in regulation and quality assurance.

Intertek’s history makes the issue particularly striking. The company entered the public market at a valuation of approximately £614 million in 2002. The proposed transaction values the enterprise at roughly £10.9 billion. Public markets supported a significant period of expansion, but private capital may capture the next stage of portfolio restructuring and consolidation.

This raises a broader policy question. A stock exchange cannot rebuild its reputation solely by improving listing rules if existing companies continue to believe that private buyers will assign greater value to their strategies than public investors.

Intertek is not a household consumer brand, which may limit political concern. Yet that is precisely why the deal matters. London risks losing the quiet compounders that provide depth and diversity to its market, not only the companies that generate dramatic headlines.

What does Intertek’s share price say about completion confidence and residual deal risk?

Intertek shares closed at approximately 5,805 pence on June 19, near the top of a 52-week range extending from about 3,519 pence to 5,820 pence. The shares gained roughly 2.6% over the preceding five trading sessions and approximately 6.2% over one month.

The market price remained around 3.4% below the £60 cash consideration. That discount represents the time until completion, the opportunity cost of holding the shares and the remaining possibility that shareholder, court or regulatory conditions are not satisfied.

The final dividend requires separate treatment. Investors who acquired shares after the relevant record date are not entitled to the 107.7 pence payment. For those investors, the appropriate merger-arbitrage comparison is principally between the market price and the £60 cash offer, not the total £61.077 headline value.

Investor sentiment is therefore positive but transaction-driven. The share price no longer reflects only Intertek’s standalone earnings prospects. It represents the market’s probability-adjusted assessment of the takeover completing on the agreed terms.

The narrow spread suggests investors expect completion, but the downside could be significant if the transaction fails. Without the offer, Intertek would return to its standalone strategic review and the market would have to reassess the company without a guaranteed cash exit.

What execution risks could turn EQT’s strategic prize into a complicated ownership test?

The first risk is regulatory and procedural. The transaction requires shareholder support, court approval and regulatory clearances across relevant jurisdictions. Intertek operates internationally and serves sensitive industries, increasing the complexity of the approval process.

The second risk is financing. Higher interest costs or weaker credit markets could affect the permanent financing structure, even though interim facilities and equity commitments support the agreed offer.

The third risk is portfolio strategy. EQT must decide whether Intertek Testing and Assurance and Intertek Energy and Infrastructure create more value together or separately. A sale or demerger could unlock valuation, but it could also remove shared customer relationships, technical capabilities or geographic infrastructure.

The fourth risk is acquisition execution. Buying smaller laboratories can accelerate growth, but poor integration can create inconsistent systems, employee departures and quality-control problems.

The fifth risk is cultural. Intertek’s commercial value rests on independence, scientific judgment and credibility. Private ownership must not create incentives that encourage speed, volume or cost savings at the expense of reliable testing.

The final risk is the exit strategy. EQT will eventually need to sell, relist or recapitalise the business. The success of that exit will depend on whether Intertek grows earnings and strategic value faster than debt and acquisition complexity accumulate.

Intertek has spent more than 140 years reducing risk for other companies. Under EQT, it will have to demonstrate that the same discipline can be applied to its own transformation.

Key takeaways on how Intertek became a £10.9 billion private equity prize for EQT

• Intertek evolved from nineteenth-century cargo, chemical and electrical testing businesses into a global assurance network spanning more than 100 countries.
• The company’s value comes from reducing regulatory, safety and commercial uncertainty rather than from selling a single product.
• Intertek generated £3.43 billion of revenue and approximately £620 million of adjusted operating profit in 2025.
• Recurring compliance demand, high cash conversion and customer diversification make Intertek particularly suitable for acquisition financing.
• Intertek’s proposed separation into Testing and Assurance and Energy and Infrastructure revealed a potentially significant portfolio valuation gap.
• EQT’s strategy is likely to combine portfolio restructuring, digital investment and bolt-on acquisitions rather than relying only on cost reduction.
• Artificial intelligence can improve laboratory workflows, but scientific independence and data security remain essential competitive assets.
• Additional leverage could improve equity returns, although it may also constrain acquisitions and organic investment if performance weakens.
• The takeover could accelerate consolidation among SGS, Bureau Veritas, Eurofins Scientific and specialist regional laboratories.
• Intertek’s likely departure adds to concern that London public markets are surrendering high-quality global businesses to private capital.